SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $5,340,558,034 |
| Positions | 28 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | COM | $1,191,348,571 | 6,361,323 |
| NUVALENT INC | NUVL | COM | $731,667,476 | 5,924,433 |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $415,053,937 | 10,215,455 |
| GENMAB A/S | GMAB | SPONSORED ADS | $360,767,109 | 13,133,131 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $340,984,271 | 3,840,778 |
| APOGEE THERAPEUTICS INC | APGE | COM | $209,233,581 | 1,576,385 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $204,094,539 | 2,144,526 |
| TANGO THERAPEUTICS INC | TNGX | COM | $198,736,169 | 6,357,523 |
| BELITE BIO INC | BLTE | SPONSORED ADS | $189,844,565 | 1,232,877 |
| ERASCA INC | ERAS | COM | $174,956,000 | 9,550,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.